How Should Drug Trials Be Conducted In The Middle Of An Ebola Outbreak?
Monday, February 16, 2015
We're sorry. This audio clip is no longer available. A transcript for audioclip 23751 has been made available.
Although U.S. troops are coming home from West Africa after aiding in the Ebola outbreak — the fight against the disease continues.
Health officials will soon begin clinical trials of an anti-Ebola drug, ZMapp, but they'll face ethical challenges.The drug was developed by the San Diego-based company Mapp Biopharmaceutical.
Michael Kalichman, co-founder and director of the Center for Ethics in Science and Technology at UC San Diego, said it can be ethically challenging for doctors to decide which patients will be given the anti-Ebola drug.
Kalichman said some patients will be given supportive care while others will be given ZMapp.
"What you want in a clinical trial is something to compare to," Kalichman told KPBS Midday Edition on Monday. "One group gets Zmapp and the other gets the best supportive care. This is an example of how extraordinarily difficult a trial can be."
Kalichman, who is also the director of the Research Ethics Program at UC San Diego, said there are two possible outcomes from the clinical trial.
"One is that it works well. The other possibility is that it makes things worse, perhaps the disease itself is already worse," he said.
Jamal Gwathney, a doctor with the Commissioned Corps of the U.S. Public Health Service who worked in Liberia for nearly two months last year, said the number of new cases has decreased, but health officials have a goal of eliminating all cases.
"The cases are definitely significantly lower than when the epidemic started," said Gwathney, who is also the clinical director at the federal jail in downtown San Diego. "Sierra Leone is the hardest hit of Ebola right now. We're doing everything, trying to impact that and getting it down to zero."
To view PDF documents, Download Acrobat Reader.